Kepler Capital analyst Christophe dombu maintained a Buy rating on Basilea Pharmaceutica (BSLN – Research Report) on February 7 and set a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback